Aclarion Inc. (ACON)
ACON trades on Nasdaq in Health Care, Medical Specialities. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1635077/000168316826001986/0001683168-26-001986-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ACON on Nasdaq |
| Sector | Health Care |
| Industry | Medical Specialities |
| Country | United States |
| IPO year | 2022 |
| SEC CIK | 0001635077 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $76K |
| Net income | -$7.2M |
| Operating income | -$7.1M |
| Net margin | -9551.9% |
| Operating margin | -9312.5% |
| Revenue growth | +65.6% |
| Cash | $12.0M |
| Total assets | $13.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 52.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $14.2M cash; operating cash flow -$2.2M a quarter. | Report 2026-09-30 |
| Shares outstanding | 2,882,370 (2026-11-03); 671,371 a year earlier; 8,793,010 three years earlier. 3y figure adjusted for splits (1-for-144720 overall). | Cover page 2026-11-03 |
| Reverse splits, 3 years | 3; latest 1-for-27 on 2025-03-28 | Source 2025-03-28 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-01-09 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Haynie & Company, Salt Lake City, Utah, United States | PCAOB Form AP 2026-03-20 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $177K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $34K | -$2.6M | -$2.0M | $14.2M | No debt tags | $99K | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $25K | -$2.7M | -$2.7M | $16.3M | No debt tags | $84K | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $21K | -$2.9M | -$2.6M | $19.0M | No debt tags | $78K | 10-Q 2026-05-13 |
| Q4 2025 2025-12-31 | $18K | -$1.9M | -$1.6M | $12.0M | No debt tags | $76K | 10-K 2026-03-18 |
| Q3 2025 2025-09-30 | $19K | -$1.7M | -$1.2M | $11.3M | No debt tags | $67K | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $19K | -$1.6M | -$1.9M | $12.8M | No debt tags | $63K | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $19K | -$2.0M | -$2.5M | $14.8M | No debt tags | $55K | 10-Q 2026-05-13 |
| Q4 2024 2024-12-31 | $10K | -$2.0M | -$923K | $454K | $0 | $46K | 10-K 2026-03-18 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.
Price moves
| Window | Return |
|---|---|
| 1 week | -6.0% |
| 1 month | -27.1% |
| 3 months | -35.0% |
| Year to date | -66.1% |
| 1 year | -74.6% |
| From 52-week high | -80.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| ACONW | Aclarion Inc. Warrant | $0.0214 |
Peers in Medical Specialities
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ADVB | Advanced Biomed Inc. | $2.22 | -12.25% | $3.7M |
| ACH | Accendra Health Inc. | $0.0857 | -35.08% | $6.6M |
| BGLC | BioNexus Gene Lab Corp | $0.8200 | -0.12% | $2.4M |
| AMS | American Shared Hospital Services | $1.07 | -0.93% | $7.1M |
| MDXH | MDxHealth SA | $0.1490 | +3.40% | $14.2M |
| SERA | Sera Prognostics Inc. | $1.94 | -3.48% | $77.2M |
| XGN | Exagen Inc. | $3.77 | -8.72% | $96.2M |
| BDSX | Biodesix Inc. | $9.00 | -8.91% | $99.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier